A Deeper Dive Into Design Therapeutics
Design Therapeutics Inc DSGN
$12.18
▼ -3.49%
($-0.44)
🔥 High Short Interest
📅 Earnings This Week
Open
$12.62
Prev Close
$12.62
Day Range
$12.06 – $13.36
52W Range
$3.76 – $17.25
Market Cap
$760.73M
Beta
1.63
EPS (TTM)
$-1.19
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-03-26 |
| Shares Out. | 62,460,000 |
| Website | designtx.com/ ↗ |
| Phone | 18009279800 |
| Employees | 54 |
| Net Income | -$17.6M |
| Free Cash Flow | -$54.1M |
| Total Assets | $230.4M |
| Total Liabilities | $12.4M |
| Equity | $218.1M |
About Design Therapeutics Inc
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Design Therapeutics Inc is a publicly traded company under the ticker symbol DSGN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)